Senseonics Stock News

Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.

Senseonics Holdings, Inc. ( SENS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Matthew Miksic - Barclays Bank PLC, Research Division Joshua Jennings - TD Cowen, Research Division Anthony Petrone - Mizuho Securities...

GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, ...

Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, imp...

Senseonics Holdings, Inc. (NYSE:SENS ) Eversense 365 Commercial Update Conference Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Brian Hansen - Ascensia Diabetes Care Us Inc. Matthew Miksic - Barclays Bank PLC, Research Division Anthony Petrone - Mizuho Securities USA...

TOKYO--(BUSINESS WIRE)--PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Hold...

CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md.

Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frederick T. Sullivan - CFO, Secretary & Treasurer Mukul Jain - Chief Operating Officer Timothy T.